• Erasca's third-quarter 2026 net loss widened 68% year over year to $51.33 million.
• Research and development expenses more than doubled year over year to $47.2 million, driven partly by higher clinical trial costs.
• Cash, cash equivalents and marketable securities totaled $947.8 million at September 30, sufficient to fund planned key milestones.
• ERAS-0015 received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma in August 2026.
• Three potentially registration-enabling pancreatic and lung cancer trials are expected to begin from the first half of 2027 through early 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121601PRIMZONEFULLFEED9876306) on November 12, 2026, and is solely responsible for the information contained therein.